Foot and Ankle Specialist practicing for over 30 years in the Hudson Valley. Operates six successful practices in the New York Market. His passion has.

Slides:



Advertisements
Similar presentations
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Advertisements

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Implementing NICE guidance
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.
Implementation of CYP2C19 Genotyping for Clopidogrel Gwen McMillin, PhD, DABCC (CC,TC) July 27, 2010.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
January 16, 2010 Monica Robinson Green, PharmD, BCPS.
Presenter Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference.
Personalized Medicine Presentation by: Alex Wiki by: John and Lydia.
Lesson 9 Objectives: To describe the role of biotechnology in developing new medicines – pharmacogenomics.
What Do Toxicologists Do?
Personalized Medicine
Individualized Medicine Pharmacogentics
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Cancer Clinical Trials:
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Plan Year. 2 WHAT’S NOT CHANGING FOR 2014  Premiums will remain the SAME  First Choice providers and Generic Medications are STILL NO COST TO.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
WellFirst Discount Plans. What are WellFirst Discount Plans?  The WellFirst Discount Plans offer one of the most extensive consumer-driven savings programs.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
 Lotricia Guerrier, ARNP/CNS, CCNS, FNP-BC, CCRN.
Who Are We? Molecular Testing Labs is a cutting-edge molecular and genetics testing laboratory focused on pharmacogenomics. Our primary goal is to provide.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Sales Trainer for PGXL Laboratories
National e-Prescribing Conference Sponsored by CMS and Industry Partners - October 6 & 7, 2008 Florida Agency for Health Care Administration Florida Center.
Pharmacy Services.
Richard D. Hockett, Jr. M.D. Sr. Clinical Research Physician Group Leader, Genomic Medicine FDA Clinical Pharmacology Advisory Committee Integrating Pharmacogenomics.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Medication/ Medication Administration
The University of Mississippi Medical Center
20 Beginning of the chapter
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
K NOWLEDGE S ERVICE E XPERIENCE Integrated Clinical Solutions.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
March 10, 2014 NURS 330 Human Reproductive Health.
OUTLINE OF HEALTH CARE PLAN RICHARD R. SCHNEIDER, MD F.A.C.P., F.A.C.C.
 A test of a new intervention or treatment on people.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Bledsoe et al., Paramedic Care Principles & Practice Volume 1: Introduction © 2006 by Pearson Education, Inc. Upper Saddle River, NJ Basic Pharmacology.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Introduction to Pharmacology. ORIENTATION TO PHARMACOLOGY Objectives: 1. Definition of the four basic terms (drug, pharmacology, clinical pharmacology,
Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.
Pharmacogenetics.
Integrating Pharmacogenomic Questions Into GCIG Ovarian Cancer Clinical Trials Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research.
Life Expectancy and Physiological Age Complementary and Alternative Medicine Quackery and Fraud Deciding Your Fitness Future Selecting a Fitness Facility.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Drug efficacy is questioned.. Variation in drug responses.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
New research areas in personalised medicines
PGx Logical Overview.
Pharmacogenomics: towards personalized medicine
Pharmacogenomics Rita Leone, RN, MSN, CMSRN.
Mahla sattarzadeh Kerman University of Medical Sciences
Pharmacogenomics Genes and Drugs.
Lung Cancer Screening Sandra Starnes, MD Professor of Surgery
Safe and Appropriate Use of Opiates
Personalised Medicine ‘into the future’
Pharmacogenetics and Pharmacoepidemiology “PHCY 480”
For Nurses and healthcare providers
Introduction to Pharmacogenetics
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Presentation transcript:

Foot and Ankle Specialist practicing for over 30 years in the Hudson Valley. Operates six successful practices in the New York Market. His passion has always been health, wellness and changing lives through leadership and inspiring individuals to challenge their limits. Dr. Tumen has completed 9 Marathons including the NYC Marathon 7 times and enjoys endurance trail runs. Dr. Doug Tumen Operates 6 practices in the Hudson Valley NY Scientific Advisory Board Member

Fastest turn-around time business days Developed the solution for processing PGX Developed over 500 tests, incl early cancer screening that detects some types of cancer up to 6 months earlier than any other test Far superior toxicology results (tests for 56 drugs) Move urine specimens with blood immediately to early cancer screen, so can be detected earlier Revenue sharing program for qualified facilities Easy to read reports Advisors available for consultation daily FREE SUPPLIES & SHIPPING WALLET CARD for quick reference for any dr

Pharmacogenetics is the study of genetic variations that influence individual response to drugs. “It is the science that allows us to predict a response to drugs, on an individual’s complete genetic makeup.” − Felix Frueh, Associate Director of Genomics, FDA Helps prescribers individualize drug therapy, decrease the chance for adverse drug events, and increase the effectiveness of drugs.

Pharmacogenomics = Tailored drug therapy based on genetically determined variation to increase effectiveness and decrease side effects. To the physician this will mean: Better, safer drugs the first time - Recovery time will go down and safety will go up as the likelihood of adverse reactions goes down, or is eliminated altogether. More accurate methods of determining appropriate drug dosages Current methods of basing dosages on weight and age will be replaced with dosages based on a person's genetics as an additional and critical biomarker --how well the body processes the medicine and the time it takes to metabolize it.” From the website of the American Medical Association medicine/current-topics/pharmacogenomics.page?

Availability of testing in your medical practice with ease Non-invasive buccal swab. Covered by most insurance companies OB: refer to Black Box Warning of Codeine and other analgesics PharmD reports are included with tests: equivalent to private, individual Consult for each patient discussing drug – gene, drug –drug interactions with recommendations for alternatives. Financial Exposure to Patient: One-time, lifetime test for patient vs other routine tests such as CBCs that over a lifetime equal much more overall cost. Potential Rx savings on unnecessary drugs when precise dosing is achieved first time around. Weigh risk – benefit – one-time cost; peace of mind for patient and physician; better patient satisfaction and compliance, better outcome; less liability to physician.

Eliminate trial and error : “Right Drug, Right Dose, Right Indication, Right Patient, Right Time” Eliminate “One Size Fits All”medication management Enhance Patient Care Enhance Patient Satisfaction Enhance Compliance Risk Management : Reduce liability to physician

Higher than standard dosage required to achieve the desired results. Severe adverse drug reactions observed. Unexpected or unexplained response to medications. Multiple unsuccessful drug trials. Health issues in multiple organ systems. Multiple drug types prescribed. Patients with the following scenarios may benefit from PGT Simple screening questions of pain patients will offer to a provider enough information to make a “suspicious” or “probable” WDx of a genetic metabolic defect. If you had surgery or dental work, did you need extra anesthesia or pain medication? Have you taken hydrocodone? How did you feel after taking it? Did you get relief? Did you need higher than usual dosage? Are you allergic to medications? Do you regularly drink grapefruit, cranberry or pomegranate juice? Do you take herbal supplements?

Manufacturers recommend pharmacogenetic testing prior to or soon after initiation of therapy. FDA has also posted 16 drugs where it requires pharmacogenetic testing prior to prescribing htm

Cleveland Clinic Journal of Medicine, Volume 78, Number 4, April 2011

Inhibitor – A substrate(drug) that slows down or “inhibits” the metabolism of other substrates Inducer – A substrate that increase the elimination of other substrates Pro-drug – A substrate that is biologically inactive in its original (parent) form. These drugs must be metabolized (“activated”)before they are work in the body and produce their desired effect

Drug Metabolizing Phenotype Ultra Rapid Metabolizers ( UM ) Increased enzyme Extensive Metabolizers ( EM ) Normal Intermediate Metabolizers (IM ) Impaired Poor Metabolizers ( PM ) Non functional

Major CYP450 Isoforms 1. A2 6. 2D6 2. 2B6 7. 2E1 3. 2C8 8. 3A4 4. 2C A5 5. 2C A7

S Scenario #1- If a Physician group of 5 doctors performs 500 Paps/month with 75 biopsies & 20 $41 per biopsy and $60/IHC = $ 3, High Risk Pap $200/case = 14, TERC $140/case = 7, Urine $31/case = 6, Urine Feulgen $14/case = 2, UroVysion $56/case = 6,720 » Total Monthly PC Revenue$41,113 » Total Annual PC Revenue$493,356 » *Physician group must pay a local pathologist out of the PC revenue DNA Testing Custom Compounds

Eliminate trial and error: No more guess work “Right Dose, Right Drug, First Time, Every Time” Enhance patient care, Enhance patient satisfaction, Enhance patient compliance, Enhance patient confidence, Enhance patient outcome Private Consult with your patients on PharmD before prescribing Risk Management: Reduce liability to physician One Question Remains: You have reviewed the risks and benefits of implementing Pharmacogenetics Testing into your Medical Practice: Why Wouldn‘t You Begin Testing Your Patients Now?

Partnership Examples Scenario #2- If a Physician group of 10 doctors performs 1,000 Paps/month with 150 biopsies & 40 $41 per biopsy and $60/IHC = $ 7, High Risk Pap $200/case = 28, TERC $140/case = 15, Urine $31/case = 12, Urine Feulgen $14/case = 5, UroVysion $56/case = 13,440 Total Monthly PC Revenue$82,226 Total Annual PC Revenue$986,712 *Physician group must pay a local pathologist out of the PC revenue